Search Results - "Moiola, L."

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience by S, Guerrieri, S, Lazzarin, C, Zanetta, A, Nozzolillo, M, Filippi, L, Moiola

“…Background Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or…”
Get full text

Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients by Radaelli, M, Moiola, L, Sangalli, F, Esposito, F, Barcella, V, Ferrè, L, Rodegher, M, Colombo, B, Fazio, R, Martinelli, V, Comi, G

“…Objective: To assess the long-term benefit-risk profile of repeated courses of rituximab in Caucasian patients affected by neuromyelitis optica (NMO) and…”
Get full text

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial by Comi, G, Prof, Martinelli, V, MD, Rodegher, M, MD, Moiola, L, MD, Bajenaru, O, Prof, Carra, A, Prof, Elovaara, I, Prof, Fazekas, F, Prof, Hartung, HP, Prof, Hillert, J, Prof, King, J, MD, Komoly, S, Prof, Lubetzki, C, Prof, Montalban, X, Prof, Myhr, KM, Prof, Ravnborg, M, MD, Rieckmann, P, Prof, Wynn, D, MD, Young, C, Prof, Filippi, M, MD

“…Summary Background Glatiramer acetate, approved for the treatment of relapsing-remitting multiple sclerosis, reduces relapses and disease activity and burden…”
Get full text

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study by Annovazzi, Pietro, Capobianco, M., Moiola, L., Patti, F., Frau, J., Uccelli, A., Centonze, D., Perini, P., Tortorella, C., Prosperini, L., Lus, G., Fuiani, A., Falcini, M., Martinelli, V., Comi, G., Ghezzi, A.

“…Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more…”
Get full text

Structural and functional brain connectomes in patients with systemic lupus erythematosus by Preziosa, P., Rocca, M. A., Ramirez, G. A., Bozzolo, E. P., Canti, V., Pagani, E., Valsasina, P., Moiola, L., Rovere‐Querini, P., Manfredi, A. A., Filippi, M.

“…Background and purpose Systemic lupus erythematosus (SLE) is an immune‐mediated disease that may affect the nervous system. We explored the topographical…”
Get full text

Cognitive and psychosocial features in childhood and juvenile MS: Two-year follow-up by AMATO, M. P, GORETTI, B, VECCHIO, R, POZZILLI, C, BIANCHI, V, ROSCIO, M, MARTINELLI, V, COMI, G, PORTACCIO, E, TROJANO, M, GHEZZI, A, LORI, S, ZIPOLI, V, MOIOLA, L, FALAUTANO, M, DE CARO, M. F, VITERBO, R, PATTI, F

“…To assess the evolution of cognitive and psychosocial functioning in a cohort of childhood and juvenile multiple sclerosis (MS) cases after a mean period of 2…”
Get full text

Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients by Sferruzza, G., Clarelli, F., Mascia, E., Ferrè, L., Ottoboni, L., Sorosina, M., Santoro, S., Moiola, L., Martinelli, V., Comi, G., Martinelli Boneschi, F., Filippi, M., Provero, P., Esposito, Federica

“…Fingolimod (FTY), a second-line oral drug approved for relapsing remitting Multiple Sclerosis (RRMS) acts in preventing lymphocyte migration outside lymph…”
Get full text

Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes by Martinelli, V., Dalla Costa, G., Messina, M. J., Di Maggio, G., Sangalli, F., Moiola, L., Rodegher, M., Colombo, B., Furlan, R., Leocani, L., Falini, A., Comi, G.

“…Objectives Since its introduction, MRI had a major impact on the early and more precise diagnosis of multiple sclerosis (MS), and the 2010 diagnostic criteria…”
Get full text

Breastfeeding is not related to postpartum relapses in multiple sclerosis by PORTACCIO, E, GHEZZI, A, POZZILLI, C, DE GIGLIO, L, TOTARO, R, LUGARESI, A, DE LUCA, G, PAOLICELLI, D, MARROSU, M. G, COMI, G, TROJANO, M, AMATO, M. P, HAKIKI, B, MARTINELLI, V, MOIOLA, L, PATTI, F, LA MANTIA, L, MANCARDI, G. L, SOLARO, C, TOLA, M. R

“…To assess the relationship between breastfeeding and risk of puerperal relapses in a large cohort of patients with multiple sclerosis (MS). We prospectively…”
Get full text

Cognitive and psychosocial features of childhood and juvenile MS by AMATO, M. P, GORETTI, B, PATTI, F, VECCHIO, R, POZZILLI, C, BIANCHI, V, ROSCIO, M, COMI, G, TROJANO, M, GHEZZI, A, LORI, S, ZIPOLI, V, PORTACCIO, E, MOIOLA, L, FALAUTANO, M, DE CARO, M. F, LOPEZ, M

“…To assess the impact of multiple sclerosis (MS) on cognitive and psychosocial functioning in childhood and juvenile cases. We used an extensive…”
Get full text

Burden of rare coding variants in an Italian cohort of familial multiple sclerosis by Mascia, E., Clarelli, F., Zauli, A., Guaschino, C., Sorosina, M., Barizzone, N., Basagni, C., Santoro, S., Ferrè, L., Bonfiglio, S., Biancolini, D., Pozzato, M., Guerini, F.R., Protti, A., Liguori, M., Moiola, L., Vecchio, D., Bresolin, N., Comi, G., Filippi, M., Esposito, F., D'Alfonso, S., Martinelli-Boneschi, F.

“…Multiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative demyelinating disease of the central nervous system. It is a complex and heterogeneous…”
Get full text

Evidence of thalamic gray matter loss in pediatric multiple sclerosis by MESAROS, S, ROCCA, M. A, ABSINTA, M, GHEZZI, A, MILANI, N, MOIOLA, L, VEGGIOTTI, P, COMI, G, FILIPPI, M

“…We used voxel-based morphometry (VBM) to assess the pattern of regional gray matter (GM) loss in patients with pediatric multiple sclerosis (MS) and its…”
Get full text

Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs by Portaccio, Emilio, Ghezzi, Angelo, Hakiki, Bahia, Sturchio, Andrea, Martinelli, Vittorio, Moiola, Lucia, Patti, Francesco, Mancardi, Gian Luigi, Solaro, Claudio, Tola, Maria Rosaria, Pozzilli, Carlo, De Giglio, Laura, Totaro, Rocco, Lugaresi, Alessandra, De Luca, Giovanna, Paolicelli, Damiano, Marrosu, Maria Giovanna, Comi, Giancarlo, Trojano, Maria, Amato, Maria Pia

“…Objective To assess relapses, disability progression and the role of disease modifying drugs (DMDs) in the year after delivery in women with multiple sclerosis…”
Get full text

Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis by AMATO, M. P, PORTACCIO, E, SOLARO, C, TOLA, M. R, POZZILLI, C, DE GIGLIO, L, TOTARO, R, LUGARESI, A, DI TOMMASO, V, PAOLICELLI, D, MARROSU, M. G, COMI, G, GHEZZI, A, PELLEGRINI, F, TROJANO, M, HAKIKI, B, ZIPOLI, V, MARTINELLI, V, MOIOLA, L, PATTI, F, LA MANTIA, L, MANCARDI, G. L

“…To assess pregnancy and fetal outcomes after in utero exposure to interferon-β (IFNβ) in all pregnancies occurring in women with multiple sclerosis (MS) during…”
Get full text

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis by Clarelli, F, Liberatore, G, Sorosina, M, Osiceanu, A M, Esposito, F, Mascia, E, Santoro, S, Pavan, G, Colombo, B, Moiola, L, Martinelli, V, Comi, G, Martinelli-Boneschi, F

“…The aim of the study is the identification of genetic factors that influence the long-term response to interferon-β (IFNβ) (4-year follow-up). We performed a…”
Get full text

Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases by Ghezzi, A, Pozzilli, C, Grimaldi, LME, Moiola, L, Brescia-Morra, V, Lugaresi, A, Lus, G, Rinaldi, F, Rocca, MA, Trojano, M, Bianchi, A, Comi, G, Filippi, M

“…Background: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients. Objective: The purpose of this…”
Get full text

Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis by Goretti, B, Portaccio, E, Ghezzi, A, Lori, S, Moiola, L, Falautano, M, Viterbo, R, Patti, F, Vecchio, R, Pozzilli, C, Bianchi, V, Cappiello, S, Comi, G, Trojano, M, Amato, MP

“…Background: There is limited information on fatigue and its clinical and psychosocial correlates in children and adolescents with multiple sclerosis (MS)…”
Get full text

Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients by Esposito, F., Ferrè, L., Clarelli, F., Rocca, M. A., Sferruzza, G., Storelli, L., Radaelli, M., Sangalli, F., Moiola, L., Colombo, B., Martinelli Boneschi, F., Comi, G., Filippi, M., Martinelli, V.

“…Background Treatment choice in multiple sclerosis (MS) is crucial for optimizing risk–benefit profile. Objective To assess fingolimod (FTY) effectiveness and…”
Get full text

Safety and efficacy of natalizumab in children with multiple sclerosis by GHEZZI, A, POZZILLI, C, SARCHIELLI, P, ZAFFARONI, M, COMI, G, GRIMALDI, L. M. E, BRESCIA MORRA, V, BORTOLON, F, CAPRA, R, FILIPPI, M, MOIOLA, L, ROCCA, M. A, ROTTOLI, M

“…To describe the effect of natalizumab in the treatment of subjects with active multiple sclerosis (MS) treated before the age of 18 years. Nineteen pediatric…”
Get full text

Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report by Pisa, M., Della Valle, P., Coluccia, A., Martinelli, V., Comi, G., D'Angelo, A., Moiola, L.

“…•Alemtuzumab is effective in highly active multiple sclerosis even when all other treatments fail in achieving disease control.•The most important adverse…”
Get full text